An observational study in Diabetic Retinopathy, Diabetes Mellitus, Type 2 and Diabetic Complication, sponsored by Association for Innovation and Biomedical Research on Light and Image. Recruiting at 1 site in Portugal. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image — 2 open to participants now, 3 under way, none of them phase 3. Diabetic Retinopathy · Association for Innovation and Biomedical Research on Light and Image.
Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, this one is the 7th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2025, is one of 16 observational ones, and was the 18th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image are open now, in 1 country. Recruiting first, the newest first:
Association for Innovation and Biomedical Research on Light and Image · Sites in Portugal
Ages 35–90
By country, each count listing its studies:
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 100 is below the median of 173 across 265 observational studies indexed under Diabetic Retinopathy.
Median enrollment 84 across the 2 interventional studies, 81 across the 16 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Association for Innovation and Biomedical Research on Light and Image is the lead sponsor of 38 studies on the registry; 5 are open to participants now.
2 of the studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07417410Association for Innovation and Biomedical Research on Light and ImageAnalysis of DR Progression to Identify Risks and Need for Treatment | 2026-11 |
| NCT07458516Association for Innovation and Biomedical Research on Light and ImageLongitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to explore structural and functional imaging and systemic biomarkers of diabetic retinopathy (DR) progression, in eyes from Type 2 Diabetes (T2D) patients with moderate to severe non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR) using state of the art methodologies, commonly applied in clinical practice, over a period of two years. This study will provide longitudinal data to better understand retinal changes in moderate to severe diabetic retinopathy and early proliferative diabetic retinopathy and help guide timely interventions to prevent vision loss. One or two eligible eyes per participant may be included in the study. The study will evaluate retinal vascular closure, ischemia, leakage, neurodegeneration, macular edema and microaneurysm dynamics and their association with disease progression.
Diabetes Mellitus (DM) is an important public health problem, affecting about 589 million people in the world, and expected to reach 853 million by 2050. Active screening for DR is important because most patients may be asymptomatic until the very late stages. Nonproliferative diabetic retinopathy (NPDR) itself may be associated with reduced visual function and quality of life measures (Willis et al., 2017).
The molecular pathophysiology of DR is complex, and a complete model of the disease is still being elucidated. The oxidative stress in diabetes upregulates multiple cytokines and chemokines, such as vascular endothelial growth factor (VEGF), angiopoietins, tumour necrosis factor (TNF), interleukins (ILs) and matrix metalloproteinases (MMPs) that leads to breakdown of the blood-retinal-barrier (BRB). Also, retinal capillary obstruction (leukostasis) or dropout (apoptosis of vascular cells) in diabetes leads to tissue ischemia and hypoxia causing increased retinal VEGF expression through transcriptional regulation by hypoxia-inducible factor 1 alpha (HIF-1α) (Arjamaa \& Nikinmaa, 2006; Whitehead et al., 2019).
The risk of developing DR complications increases over time, with increasing areas of capillary nonperfusion underpinning progression to more severe forms and development of complications as PDR or diabetic macular edema (DME), driven by hypoxia and hyperexpression of proangiogenic growth factors. However, this risk varies widely, independently of metabolic control. Differentiating patients with higher risk of progression and development of vision-threatening complications (VTC; DME and PDR) is of paramount importance for efficient treatment of the disease in order to prevent vision disability and achieve better visual outcomes. Recent developments in terms of retina imageology, namely Optical Coherence Tomography (OCT) and OCT Angiography (OCTA), have improved the understanding of DR pathophysiology and evolution, with a better characterization of venous abnormalities including occlusion, tortuosity, dilatation, looping or beading. OCTA examination is faster and safer compared to examination with fluorescein angiography (FA), and it can visualise the retinal vasculature in any layer of the retina. OCTA has the potential to become the examination of choice to identify eyes at risk of progression and development of VTC. Ultra-widefield fluorescein angiography (UWF-FFA) further enables the assessment of retinal ischemia and retinal leakage over a wider retinal area, providing additional biomarkers of disease severity and progression.
The purpose of this observational, non-interventional, prospective, and longitudinal clinical study is to explore explore structural and functional imaging and systemic biomarkers of diabetic retinopathy (DR) progression, in eyes from Type 2 Diabetes (T2D) patients with moderate to severe NPDR and mild PDR - Diabetic Retinopathy Severity Scale (DRSS) levels 43, 47, 53, and 61 - using state of the art methodologies, commonly applied in clinical practice. One or two eligible eyes from the same participant may be included in the study if all eligibility criteria are met.
Follow-up visits will be performed every 6 months for 2 years with a total of 5 visits. Participants will undergo the following assessments: multimodal retinal imaging, including OCT, OCTA, ultra-widefield (UWF) fundus fluorescein angiography (FFA) and fundus photography (FP), and color fundus photography (CFP); functional testing: best corrected visual acuity (BCVA) and microperimetry (Macular Integrity Assessment, MAIA); collection of systemic health variables, including glycated hemoglobin (HbA1c), blood pressure, diabetes duration, and relevant comorbidities. UWF-FFA assessments will be used to quantify both ischemic and leakage areas and to evaluate their longitudinal changes over time. Statistical analyses will account for repeated measurements and potential inter-eye correlation when both eyes from the same participant are included.
Study Population: Eyes with moderate to severe NPDR and mild PDR. Ideally, the distribution of eyes will be as follows: 40 for Diabetic Retinopathy Severity Scale (DRSS) level 43, 40 for DRSS level 47, and 20 for DRSS levels 53-61
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Changes in capillary perfusion density (PD) using OCTA
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in capillary non-perfusion using binarized vessel density (VD) as perfusion density (PD) in the superficial and deep retinal vascular layers assessed with Optical Coherence Tomography Angiography.
Time frame: Baseline to 24 months
Foveal Avascular Zone (FAZ) area
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the area of the foveal avascular zone measured in square millimeters (mm²) using Optical Coherence Tomography Angiography automated segmentation tools across DRSS levels.
Time frame: Baseline to 24 months
Foveal Avascular Zone (FAZ) perimeter
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the perimeter of the foveal avascular zone measured in millimeters (mm) using Optical Coherence Tomography Angiography automated segmentation tools across DRSS levels.
Time frame: Baseline to 24 months
Foveal Avascular Zone (FAZ) circularity
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the circularity of the foveal avascular zone using Optical Coherence Tomography Angiography automated segmentation tools across DRSS levels.
Time frame: Baseline to 24 months
Changes in retinal ischemic area using UWF FFA
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in retinal ischemic area (mm2) across DRSS levels.
Time frame: Baseline to 24 months
Changes in central retinal thickness (CRT)
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Central Retinal Thickness (CRT) assessed using Optical Coherence Tomography (OCT) across DRSS levels.
Time frame: Baseline to 24 months
Changes in central intraretinal fluid
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in intraretinal fluid (layer-specific) assessed using Optical Coherence Tomography (OCT) across DRSS levels.
Time frame: Baseline to 24 months
Changes in Disorganisation of Retinal Inner Layers (DRIL)
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Disorganisation of Retinal Inner Layers (DRIL) assessed using Optical Coherence Tomography (OCT) across DRSS levels.
Time frame: Baseline to 24 months
Changes in Disorganisation of Retinal Outer Layers (DROL)
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Disorganisation of Retinal Outer Layers (DROL) assessed using Optical Coherence Tomography (OCT) across DRSS levels.
Time frame: Baseline to 24 months
Changes in Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL) thickness
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL) thickness assessed using Optical Coherence Tomography (OCT) across DRSS levels.
Time frame: Baseline to 24 months
DRSS severity level
Evaluate the DRSS score (range 10-85; higher scores indicate worse severity) in Ultra-widefield fundus photography (UWF-FP).
Time frame: Baseline to 24 months
Changes in microaneurysm (MA) count
Evaluate baseline differences and longitudinal changes (from baseline to months 6, 12, and 24) in MA number in colour fundus photography (CFP field 2) across DRSS levels.
Time frame: Baseline to 24 months
Changes in microaneurysm (MA) turnover
Evaluate baseline differences and longitudinal changes (from baseline to months 6, 12, and 24) in MA turnover in colour fundus photography (CFP field 2) across DRSS levels.
Time frame: Baseline to 24 months
Changes in retinal leakage area using UWF-FFA
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in retinal leakage area measured using ultra-widefield fluorescein angiography (UWF-FFA).
Time frame: Baseline to Month 24
Changes in DRSS levels
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in DRSS classification, including one-step and two-step changes across DRSS levels using ultra-widefield fluorescein angiography (UWF-FFA).
Time frame: Baseline to 24 months
Changes in Best Corrected Visual Acuity (BCVA)
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in BCVA, measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity.
Time frame: Baseline to 24 months
Macular sensitivity using Microperimetry
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in average macular sensitivity (dB), fixation indices P1 and P2 (%), and Bivariate Contour Ellipse Area (BCEA; 63% and 95%) across DRSS levels.
Time frame: Baseline to 24 months
Changes in Intraretinal Microvascular Abnormalities (IRMAs)
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the presence and area of IRMAs using Swept-Source OCTA, UWF-FP and UWF-FFA.
Time frame: Baseline to 24 months
Changes in neovascularization (NV)
Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the presence and area of NV using Swept-Source OCTA, UWF-FP and UWF-FFA.
Time frame: Baseline to 24 months
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.
Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 24 months is below that.
Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2027 → Nov 2027 and completion Jun 2028 → Nov 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association for Innovation and Biomedical Research on Light and Image